Hemophilia Management


Advisory Board

Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
Medical Advisor
National Hemophilia Foundation

Jennifer Maahs, RN, PNP, MSN
Nurse Practitioner
Indiana Hemophilia and Thrombosis Center

Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.

Hemophilia Quick Facts

  • Because of high health care expenditures for hemophilia (mean per patient cost in a commercial population is $155,000/year and $697,000/year for a patient with inhibitors), some health plans have increased cost sharing between insurers and patients with the patient assuming a larger amount of the costs.
  • High cost-sharing requirements (i.e., use of co-insurance) for hemophilia therapies, compared to fixed copayment, may put patients with hemophilia at risk for not being able to afford treatment.
  • A specialty tier (Tier IV) can have a co-insurance from 25% - 33% of the cost of clotting factor therapies, placing a higher amount of the financial burden on patients with hemophilia versus healthy patients.


Q: What best describes your primary role?

Q: Approximately how many patients with hemophilia are being managed in your organization or practice setting?

Q: Which of the following trends will have the greatest financial impact on the future management of hemophilia?

Stay Connected

Join the conversation